Similarly, Descovy for PrEP achieved record market share, with sales increasing 20% year-over-year to $701 million. The following slide illustrates the market leadership of these key HIV products: A ...
Gilead Sciences (NASDAQ:GILD) presented its Q2 2025 financial results on August 7, 2025, showcasing strong performance in its core HIV business and progress across its oncology pipeline. The biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback